
SurekhaYadav MD
@shiningsurekha
Followers
207
Following
601
Media
14
Statuses
243
Nuclear Medicine Physician, Molecular Imaging and Theranostics.|Tweets are my own
San Francisco, CA
Joined December 2010
Our latest study, coinciding perfectly with FDA's expanded approval of Pluvicto. Taxane-based chemo is associated with ⬇️ PSMA uptake 👉🏼EJNMMI Research: Big Thanks to @thomashopemd for his excellent mentorship & our wonderful co-authors! . More below:
2
0
4
RT @PSMAconference: What is the best combination therapy with Lu-PSMA? Let’s hear some insights from the Australian prospective trials in t….
0
5
0
RT @dr_coops: Great summary re: avoiding false positive PSMA pitfalls from Irene Burger #APCCCDiagnostics25
0
43
0
RT @gu_onc: Breaking news podcast - ENZA-P reports OS benefit for combo of enza + LuPSMA. @drlouiseemmett reports data at @ASCO GU and publ….
0
6
0
RT @UCSFimaging: The @PSMAconference will gather leading experts to discuss the latest in PSMA PET imaging & radioligand therapies. Hear fr….
0
6
0
RT @DrMHofman: SPECT deserves RESPECT! . @drlouiseemmett makes the argument that it is a powerful tool for theranostics ➤ enabling early,….
0
26
0
RT @thomashopemd: We are excited to host the second PSMA PET conference with @UCLATheranostic and the @PCF_Science in March. The abstract d….
0
10
0
Imagine the future of precision medicine with evidence that is impossible to ignore! Our latest study shows why post-treatment SPECT scans are a must. Next time you’re ordering, let these numbers do the talking!
1) We recently reported our experience with post-treatment SPECT in PSMA RLT and its impact on management. Nearly 50% of patients had a change in treatment! Post-treatment imaging has a huge impact, and allows us to follow disease at each treatment (.
1
0
6
'Patients imaged with 18F-DCFPyL demonstrated clinical benefit to PSMA RLT comparable to those imaged with 68Ga-PSMA-11, and either agent can be used for screening patients' - excerpts from our latest work @thomashopemd @koshkin85 @UCSFimaging @FrontiersIn
1
0
2
RT @UCSFimaging: New in #Theranostics from @UCSFimaging's Drs. Anil Bidkar (@anilbidkar1), Luann Zerefa, Surekha Yadav (@shiningsurekha), H….
0
4
0
Shoutout to the incredible team behind this review @anilbidkar1 @flavell_rob and Co-authors ! Grateful for the opportunity @flavell_rob and to be a part of this project!!.
Congrats to @anilbidkar1 @shiningsurekha and co-authors on the timely review on Actinium-225 targeted alpha particle therapy for prostate cancer! Lots of promise for this treatment modality. #Theranostics
0
1
7
RT @CalaisJeremie: We can do better than a fixed set of 6 cycles of LuPSMA at a 6-week time interval ! .Great multicenter data of >100 pati….
0
14
0
RT @drlouiseemmett: @thomashopemd @shiningsurekha @UCSFimaging @JournalofNucMed @SNM_MI @NANETS1 A great goal! SPECT/CT after PRRT provides….
0
2
0
Pairing of a promising project with an exceptional mentor @thomashopemd ! Excited and hopeful about the utility of SPECT/CT in #radioligandtherapies @UCSFimaging @JournalofNucMed @NANETS1.
In March, @shiningsurekha published our experience on the impact of post-treatment SPECT on patient management. We are trying to move people from thinking about SPECT as only for dosimetry, and focus on its role in response assessment and using it to follow patients over time.
0
1
11
RT @drlouiseemmett: ENZA-p trial @TheLancetOncol .Enzalutamide + adaptive-dosed (2 or 4) 177 Lu-PSMA617 vs enza al….
0
44
0
RT @CalaisJeremie: SPECT images obtained +24h after administration of Lu177 therapy can provide valuable information and can impact patient….
0
11
0
Is EXCITED about: .- Upcoming talks at #SNMMI #MidWinterMeeting by some of the distinguished figures in theranostics @thomashopemd @lisabodei @flavell_rob .- My talk on Volumetric Analysis in SSTR Imaging .- Presenting our results on Impact of Post treatment Imaging in PRRT.
0
0
11